AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01309581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 1-2 mg/kg IV as indicated for ECT
Study NCT01309581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Methohexital 1 mg/kg IV as indicated for ECT
Study NCT01926314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHENIX Neuromuscular Stimulation Therapy System device
Study NCT03801746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: IV Rifampin
Study NCT03801746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Oral Probenecid
Study NCT03801746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporins
Description: Oral Cyclosporine
Study NCT03234439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myStrength
Description: myStrength is a digital self-care behavioral and wellness platform
Study NCT00490022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrotestosterone (DHT) gel (0.7%)
Description: DHT gel, 70 mg/day for one month
Study NCT00490022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel for one month
Study NCT00023686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT00023686 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Study NCT01083498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser therapy
Description: 10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
Study NCT02221518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure & Response Prevention (EX/RP)
Description: Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
Study NCT02144545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bougie Size 33 Fr
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
Study NCT02144545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bougie Size 42 Fr
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
Study NCT02144545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distance pylorus 2 cm
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
Study NCT02144545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distance pylorus 5 cm
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
Study NCT03371173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol 30 mg (Feraccru®)
Description: Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
Study NCT03933553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy with essential oil
Description: the aromatherapy by fragrance inhalation
Study NCT01926314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual home care without device
Study NCT03933553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy with essential oil
Description: the aromatherapy by fragrance inhalation
Study NCT00794235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib (Nexavar), Dacarbazine (DTIC)
Description: Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42.
Study NCT02176434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney and hematopoietic stem cell transplantation
Description: Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
Study NCT02176434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell
Study NCT00625612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denufosol Tetrasodium (INS37217) Inhalation Solution
Description: Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
Study NCT03185793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzbromarone
Description: 25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
Study NCT05019859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low carb diet
Description: low carb diet
Study NCT00625612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
Study NCT03097497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy re-education program
Description: Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
Study NCT03690180 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum magnesium
Description: assessment of serum magnesium in all patients
Study NCT01075971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
Description: 8 mg or 16 mg daily, sublingual route on Days 1 and 2
Study NCT01075971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine hydrochloride fast dissolving tablet (FDT)
Description: 8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
Study NCT02576860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001 (Omiganan)
Description: Topical gel
Study NCT02576860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle gel
Study NCT02146677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic manipulative treatment
Study NCT02146677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham therapy
Study NCT02146677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study NCT03097497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment by GP
Description: Patients will follow the general practitioner's advice including medication if needed
Study NCT02606227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Vouchers
Study NCT02606227 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No financial incentive
Description: No financial intervention
Study NCT04947306 — intervention group
Intervention type: DEVICE
Intervention: Tetragraph® (Senzime, Uppsala, Sweden)
Description: The Tetragraph® is a recently marketed electromyographic neuromuscular monitor that uses a disposable electrode array (TetraSens) that combines stimulating and recording electrodes
Study NCT04947306 — intervention group
Intervention type: DEVICE
Intervention: TOF Watch® SX (Organon Teknika B.V., Boxtel, Holland)
Description: The TOF Watch® SX is a common used neuromuscular monitor
Study NCT01388751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: night splinting
Description: splint finger at night for 4 weeks
Study NCT02358044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
Study NCT02358044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron
Description: PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
Study NCT02358044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
Study NCT02358044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazoprevir/Elbasvir (100 mg/50 mg) FDC
Description: Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
Study NCT01636713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/VI 62.5/25
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Study NCT01636713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/VI 125/25
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Study NCT01636713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Study NCT03780959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered twice weekly by subcutaneous injection
Study NCT03780959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Administered twice weekly by subcutaneous injection
Study NCT03780959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered twice weekly by subcutaneous injection
Study NCT04493684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.
Study NCT04493684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally during each dosing day.
Study NCT04493684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (Tablet)
Description: GSK3739937 Tablet will be administered via oral route.
Study NCT03202108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krio
Description: Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian.
Study NCT04639817 — intervention group
Intervention type: DRUG
Intervention: Levofloxacin
Description: Levofloxacin administration
Study NCT04639817 — intervention group
Intervention type: DRUG
Intervention: trimethoprim-sulfamethoxazole
Description: Trimethoprim-sulfamethoxazole administration
Study NCT03283436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 0.25% Injection Solution
Description: 10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
Study NCT00221975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex
Description: Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
Study NCT00221975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Divalproex
Description: Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
Study NCT00221975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
Study NCT00221975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).
Study NCT00221975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).
Study NCT03220607 — intervention group
Intervention type: OTHER
Intervention: uterocervical angle
Description: uterocervical angle is the angle between lower segment of uterus and cervix
Study NCT03697993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine
Description: Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.
Study NCT03697993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
Study NCT02983591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol after delivery
Description: Patients will receive 1000 mcg Misoprostol per rectum
Study NCT02983591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin after delivery
Description: Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h
Study NCT02983591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin before delivery
Description: All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
Study NCT03823872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Time restricted feeding= consume food only from 12:00pm-8:00pm
Study NCT03823872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal feeding
Description: Normal feeding= consume food per normal schedule
Study NCT02423122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-745
Description: Orally-Active Selective P45 MAP Kinase inhibitor
Study NCT02449018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: QBW251 capsule(s) taken orally twice per day
Study NCT02449018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule(s) taken orally twice per day
Study NCT03645317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood tests & cardiac imaging
Description: Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
Study NCT00801060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumiliximab + FCR
Description: Dose, schedule, and duration in the protocol
Study NCT00801060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FCR
Description: Dosage, schedule, and duration in the protocol
Study NCT00860015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: 500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer.
Study NCT00860015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy.
Study NCT04276688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: 400mg/100mg twice daily for 14 days
Study NCT04276688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 400mg twice daily for 14 days
Study NCT04276688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta-1B
Description: 0.25mg subcutaneous injection alternate day for 3 days
Study NCT03371953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium
Description: A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
Study NCT03371953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Description: A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
Study NCT03371953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium + Atracurium
Description: A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
Study NCT02288013 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Closure of uterine incision at C section
Description: Closure of uterine incision at Cesarean section
Study NCT03340194 — intervention group
Intervention type: RADIATION
Intervention: Radiography
Description: Radiography of the hand and feet (face incident) the day of the inclusion
Study NCT03340194 — intervention group
Intervention type: PROCEDURE
Intervention: Veinous punction
Description: Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
Study NCT03817294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of exercise training modalities
Description: As above
Study NCT01972698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-directed and simulation-assisted training
Description: All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~* A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~* Participant will have access to an ultrasound simulator.~* Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm).
Study NCT01972698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional apprenticeship training
Description: All participants will attend an half-day ultrasound introductory course.~* Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~* Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer.
Study NCT02871687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
Study NCT02871687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
Study NCT02871687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
Study NCT04208399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 will be administered orally in fed condition.
Study NCT04990414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.